347 results about "Immunotherapeutic agent" patented technology

The invention discloses a longitudinal analysis-based lung cancer chemotherapy combined immunotherapy patient symptom prediction method, which comprises the following steps: S1, collecting a multi-modal medical data set of a patient, and carrying out data preprocessing; S2, carrying out time sequence integration on the preprocessed multi-modal medical data set to construct a longitudinal analysis data set; s3, constructing a symptom weight adaptive modeling method based on an attention mechanism; s4, forming a symptom-treatment causal relationship evaluation model; s5, inputting real-time multi-modal medical data of the patient into the symptom-treatment causal relationship evaluation model, and classifying prediction results; s6, generating an individual symptom risk assessment report of the patient according to a prediction result; s7, the clinician dynamically optimizes the chemotherapy dose, the immunotherapy dose and the drug use time of the patient based on the individualized symptom risk assessment report. The invention provides an effective technical means for accurately optimizing a lung cancer chemotherapy and immunotherapy combined scheme.

The invention discloses a tetravalent platinum autophagy inducer with a structure of a general formula I as well as a preparation method and application of the tetravalent platinum autophagy inducer. The compound disclosed by the invention has an induction effect on cell autophagy, and can be used for degrading immunosuppressive protein tenascin-C (Tenascinin-C) through autophagy so as to improve a tumor immunosuppressive microenvironment. The tetravalent platinum complex induces tumor cells to generate autophagic death through unique structural characteristics, promotes immune killer cells to infiltrate a tumor immune microenvironment, can be used for preparing novel chemical immunotherapy drugs with multiple anti-tumor mechanisms, and has broad application prospects. The problems that the traditional treatment effect is poor and a small molecule immunotherapeutic agent is lacked are solved. # imgabs0 #

Provided are methods for clinical treatment of malignant tumors (e.g., advanced solid tumors) using a combination of an anti-LAG-3 antibody, an anti-PD-1 antibody, and an immunotherapeutic agent.

The present invention relates to: a temperature-sensitive hydrogel for cancer treatment; a photothermal composition comprising the hydrogel as an active ingredient; and a preparation method for the temperature-sensitive hydrogel for cancer treatment. The temperature-sensitive hydrogel of the present invention includes gold nanostars as active ingredients, and thus can generate heat by light irradiation, thereby exhibiting a photothermal therapy effect. In addition, the hydrogel temperature increases so that the release of nitric oxide (NO) from S-nitrosocysteine can be induced. In addition, the temperature-sensitive hydrogel of the present invention includes S-nitrosocysteine as an active ingredient so that, upon a temperature rise due to a photothermal reaction, the penetration of drugs into a tumor site can be improved by the release of NO, and at the same time, apoptosis of cancer cells can be directly caused; and includes an immunotherapy agent as an active ingredient so that tumor size can be effectively suppressed even with the passage of time. Therefore, as a material that enables complex treatment combined with photothermal therapy and immunotherapy, the temperature-sensitive hydrogel of the present invention having the aforementioned effect can be usefully utilized in the field of medicine for cancer treatment.

When a cancer patient is administered an anti-cancer therapy targeting a lineage specific cell-surface antigen (e.g., CD33 (Siglec-3), CLL-1, CD123, CD327 (Siglec-6), and / or CD312 (EMR2)), e.g., in the form of an immunotherapeutic agent, the therapy can deplete not only cancer cells expressing the lineage-specific cell-surface antigen, but also noncancerous cells expressing the lineage-specific cell-surface antigen in an “on-target, off tumor” effect. This disclosure provides, e.g., novel cells having a modification (e.g., insertion or deletion) in an endogenous lineage-specific cell-surface antigen (e.g., CD33 (Siglec-3), CLL-1, CD123, CD327 (Siglec-6), and / or CD312 (EMR2)) gene. The disclosure also provides compositions, e.g., gRNAs, that can be used to make such a modification.

The invention provides multifunctional antibody-ligand traps and methods of using them to counteract immune tolerance and / or immune dysfunction. The multifunctional antibody-ligand traps and fusion proteins of the invention can counteract immune dysfunction in order to restore and unleash antitumor or pathogen-directed immune responses. Provided here are promising immunotherapeutic agents for treatment and prevention of cancers, infectious diseases, and immuno-inflammatory disorders.

In one aspect, methods are provided for assessing or treating a subject diagnosed with a tumor, comprising 1) obtaining a biological sample from the subject; 2) identifying germline or somatic mutations in the subject's genome; 3) identifying copy number profiles across the genome; 4) analyzing T cell receptor (TCR) clonotypes; and 5) identifying subjects responsive to chemotherapy, immunotherapy or combined chemotherapy and immunotherapy. In certain aspects, the identified subjects may be administered a chemotherapeutic, an immunotherapeutic or a chemotherapeutic and an immunotherapeutic, and, thereby treating the subject.

The present invention relates to an immunoprophylactic and therapeutic vaccine comprising a peripheral blood mononuclear cell loaded with a natural killer T cell ligand and an antigen, and more particularly, to an immunotherapeutic vaccine comprising a peripheral blood mononuclear cell loaded with alpha-galactosylceramide, a natural killer T cell ligand and a glycolipid. The compositions of the present invention are readily available because there is no need to isolate specific cells from peripheral blood mononuclear cells. Besides, the immunization of the peripheral blood mononuclear cells loaded with the natural killer T cell ligands and antigens not only induces the obvious-level activation of the natural killer cells and the natural killer T cells and the response of cytotoxic T lymphocytes, but also has a synergistic treatment effect in the aspect of treating malignant tumors. Therefore, the compound can be beneficially used as an anti-cancer immunotherapeutic agent.

An antitumor pharmaceutical composition including (i) a fluoropyrimidine, (ii) a B6 vitamer, and (iii) a folate for its use in the treatment of cancer in a subject in need thereof. The antitumor pharmaceutical composition may be for a simultaneous, separate, or sequential use for the treatment of cancer, and may be administered sequentially or concomitantly with one or more immunotherapeutic, chemotherapeutic or radiotherapeutic agent.

The present invention relates to a method of predicting, assessing or monitoring the sensitivity of a subject having a cancer to an immunotherapy, preferably to an immunotherapy combining at least two immunotherapeutic agents, and to corresponding kits and uses thereof. The method of predicting, assessing or monitoring the sensitivity of a subject having a tumor to an immunotherapy typically comprises a step of assessing, before any immunotherapeutic treatment step in the subject, the presence of CD4+CD25highCD39high T cells in a tumor sample of the subject, the presence of CD4+CD25highCD39high T cells in the tumor sample of the subject being indicative of sensitivity of the subject to the immunotherapy, and the absence of CD4+CD25highCD39high T cells in the tumor sample of the subject being indicative of resistance of the subject to the immunotherapy.

A chitosan-heparin nanomotor and a method for producing same are disclosed. A STING agonist-encapsulated urease-based chitosan-heparin nanomotor delivers the STING agonist directly to bladder mucosal cells in the bladder, and thus can induce an immune response.

Disclosed herein are methods of using OX40 as a biomarker for predicting clinical sensitivity and therapeutic response of subjects having cancer to treatment with immunotherapeutic agents, and methods of using OX40 as a biomarker for selecting patient population for cancer treatment with immunotherapeutic agents. Disclosed herein are also methods of treating OX40-expressing cancers using immunotherapeutic agents. Further provided herein are kit for predicting the responsiveness of a subject having cancer to treatment with immunotherapeutic agents.

A metal-organic framework (nMOF) including an X-ray sensitive prodrug is described. For instance, the MOF can include metal-containing secondary building units (SBU) that are linked together via organic bridging ligands where the SBU includes a metal cation that can absorb X-rays and where at least one organic bridging ligand is substituted by a monovalent moiety derived from a therapeutic agent, such as a chemotherapy and / or immunotherapy agent, via a group that includes a bond capable of radical-promoted bond cleavage. Methods of using the MOF to treat diseases, such as cancer, are also described. The methods can include the combination of radiotherapy or radiotherapy-radiodynamic therapy with chemotherapy or immunotherapy.

A compound for preventing and treating cancer has a first binding peptide from a urokinase-type plasminogen receptor (uPAR) antagonist, the first binding peptide being operably linked to an antibody peptide, the antibody peptide being operably linked to a second binding peptide from an endostatin or plasminogen-derived peptide sequence.

Methods and compositions using novel Cbl inhibitors enhancing expansion of immune cells to increase the efficacy of cell-based immunotherapeutics are disclosed. Also provided are cell-based immunotherapy methods and compositions.

The present invention relates to a chemo combination therapy regimen to treat cancer. More specifically, the present invention relates to a novel chemo combination therapy regimen which relates to the combination of compound AL3818 (anlotinib, catequentinib) or its pharmaceutically acceptable salts with standard platinum-based and other chemotherapy agents or immunotherapy agents. The combination of these agents should be able to provide higher efficacy than employing any agent individually.

Disclosed are methods of treating cancer using a combination of an immunotherapeutic agent, such as, for example, a PD-1, PD-L1 or CTLA-4 checkpoint inhibitor, and a glutamate modulating agent such as riluzole or trigriluzole. Pharmaceutical compositions and kits including the immunotherapeutic agents and glutamate modulating agents are also disclosed.

Novel combination therapies involving nitroxoline, its analogue or pharmaceutically acceptable salt thereof with at least one additional anti-cancer chemotherapy or immunotherapy agent are described. Related kits, pharmaceutical compositions and methods of production arlinee also described.

The present invention relates to a polypeptide for delivering an antigen to an immune cell, and more specifically, to a novel polypeptide comprising a cell membrane-permeable peptide and a peptide that binds to a surface molecule of an immune cell, a fusion polypeptide in which an antigen is bound to the polypeptide, a nucleic acid encoding the polypeptide or the fusion polypeptide, an immune cell sensitized with the fusion polypeptide or a nucleic acid encoding the same, an immunotherapeutic agent comprising the immune cell, an anti-tumor or anti-cancer vaccine, and a composition for treating a tumor or cancer.

Provided are methods and compositions for enhancing radiotherapy in various cancers by administering dopamine receptor (DRD2)‐binding phenylpiperazine derivatives such as brexpiprazole, cariprazine, pipamperone, and perospirone. In vitro studies show that combining these agents with ionizing radiation (e.g., 5 Gy) significantly reduces cancer cell survival, suppresses metastatic and stemness markers (e.g., CD44, MMP‑2, Snail, Nanog), and promotes apoptosis. Fractionated or single‐fraction radiation regimens can be paired with DRD2 antagonists to lower treatment‐resistant phenotypes, decrease the likelihood of recurrence, and potentially reduce necessary radiation dosages. The approach applies to breast, prostate, lung, pancreatic, and brain cancers, among others. Depending on tumor characteristics, additional chemotherapeutic or immunotherapeutic agents may further improve outcomes.

Described herein are compositions comprising a lanthanide (III) modified fatty acid and methods of treating cancer with the composition. In particular, the application includes a lanthanide (III) modified fatty acid is a 9-R′, 10-R″ tri octadecanoate compound. This lanthanide (III) modified fatty acid can be combined with additional therapeutic agents, such as chemotherapeutic agents, radiopharmaceuticals, hormone therapies, CDK inhibitors, epigenetic modulators, selective estrogen receptor modulators, selective estrogen receptor degraders, aromatase inhibitors, phosphatidyl inositol-3-posphate kinase inhibitors, ATP-adenosine axis-targeting agents, signal transduction inhibitors, RAS signaling inhibitors, PI3K inhibitors, arginase inhibitors, HIF inhibitors, AXL inhibitors, PAK4 inhibitors, immunotherapeutic agents, immune checkpoint inhibitors, and agonists of stimulatory or co-stimulatory immune checkpoints.

Devices, systems, and methods can be used for the automated production of dendritic cells (DC) from dendritic cell progenitors, such as monocytes obtained from peripheral blood, and the automated generation of immunotherapeutic products from those dendritic cells, all within a closed system. The invention makes it possible to obtain sufficient quantities of a subject's own DC for use in preparing and characterizing vaccines, for activating and characterizing the activation state of the subject's immune response, and to aid in preventing and / or treating cancer or infectious disease.

The present disclosure relates to biodegradable polymeric microspheres comprising a biodegradable polymer and an immunotherapeutic agent selected from the group consisting of a poly ADP ribose polymerase inhibitor (PARP inhibitor) and / or a Toll-like receptor (TLR) agonist, wherein (a) 50% of the total amount of the immunotherapeutic agent in the biodegradable polymer microspheres is released from the biodegradable polymer microspheres to a PBS solution containing 0.05% of Tween 20 at 37 DEG C at a certain time point between 3 days and 14 days; (b) releasing the immunotherapeutic agent with the dry weight of 1 mg / g to 100 mg / g from the biodegradable polymer microspheres to a PBS solution containing 0.05% of Tween 20 at 37 DEG C at a certain time point between 3 days and 14 days; or (c) satisfies both (a) and (b). Other aspects of the present disclosure relate to methods of using such microparticles and kits comprising such microparticles.

To provide a new immunotherapeutic agent useful for treating obesity.SOLUTION: The pharmaceutical composition contains a peptide having a specific amino acid sequence containing a B cell epitope. Preferably the composition includes an aluminium salt (Alhydrogel (Al (OH) 3) and monophosphoryl lipid A as adjuvants. Intramuscular administration of the composition to a subject results in the production of antibodies capable of binding to ApoB-100 in vivo, and the antibodies exert a therapeutic effect on obesity.SELECTED DRAWING: Figure 14

The present invention relates to a method for selecting a patient group predicted to respond to immunotherapy cancer treatment. According to the method of the present invention, it is possible to distinguish, in advance, between a patient group that is likely to respond to anti-TIGIT and / or anti-IL-6 immunotherapeutic agents and a patient group that is unlikely to respond to same, enabling effective treatment to be performed, and thus the method is expected to be widely applicable in the medical field.

Provided herein are multiepitope peptides comprising at least one mucin 1 (MUC1) peptide, having MHC affinity for at least one HLA serotype, and recognized by CD4+ T cell receptors and / or CD8+ T cell receptors. Also provided herein are compositions comprising the multiepitope peptides and a cationic lipid, including vaccine compositions. In various embodiments, the cationic lipid is R-DOTAP. The present invention also provides methods of using the multiepitope peptides, as well as compositions and vaccine compositions. These methods of use include methods for treating cancer in a subject and methods for inducing MUC-specific polyfunctional and cytolytic T cell responses in a subject.

Immunoglobulin complementarity determining regions ("CDRs"), and immunoglobulin binding domains comprising those CDRs, that bind human lymphocyte antigen 6 family member G6D (LY6G6D), and their use for the preparation of LY6G6D-binding proteins finding use as immunotherapeutics.

The invention belongs to the field of biological medicine, and relates to application of an SIRT2 inhibitor in preparation of a colorectal cancer medicine combined with an immunotherapeutic agent and application of the immunotherapeutic agent in preparation of the colorectal cancer medicine combined with the SIRT2 inhibitor. The research finds that the SIRT2 inhibitor AGK2 and the PD-1 antibody are used for jointly treating a colorectal cancer mouse, an obvious anti-tumor effect is achieved, and the lifetime of the colorectal cancer model mouse is prolonged. When the SIRT2 inhibitor is combined with the immunotherapeutic agent to treat colorectal cancer, a synergistic effect is achieved. The invention has a good clinical application prospect.

Tumor-selective expression of therapeutic molecules by bacteria is achieved by one or more AND, NOR, OR, NOT and / or NAND gate genetic circuits. The therapeutic molecules can be proteins, metabolites or catabolites, and may also be immunotherapeutics or immunotherapeutic cytotoxins. Single or multiple expression components may be used. Tumor selective expression of multimeric proteins utilizes multimerization as to complete the genetic circuit. Genetic circuits that are unlinked, function to achieve a combined effect on specificity of delivery of antitumor therapeutic molecules. Compositions and methods to generate silica, PEG and Poly-HPMA coated bacteria are also provided. Compositions and methods for selectively sensing or imaging tumors are also described.

This provides an improved method for treating malignant tumors in human patients. [Solution] A method comprising administering a therapeutically effective dose of a LAG-3 inhibitor; a PD-1 pathway inhibitor; and an immunotherapy agent.